A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model

Jesse A. Stoff; David E. Nix; D. W. DeYoung

doi:10.1080/08923970601067045

A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model

Jesse A. Stoff, David E. Nix, D. W. DeYoung

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.

Original language	English (US)
Pages (from-to)	601-607
Number of pages	7
Journal	Immunopharmacology and Immunotoxicology
Volume	28
Issue number	4
DOIs	https://doi.org/10.1080/08923970601067045
State	Published - Oct 2006

Keywords

Bio-engineered Lacteal Complex (BLC)
Methicillin-Resistant Staphylococcus Aureus (MRSA)
Murine Peritonitis
Sepsis
Toxemia

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Toxicology
Pharmacology

Access to Document

10.1080/08923970601067045

Cite this

@article{537749251b4f41e39cbefbe726763e5e,

title = "A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model",

abstract = "Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.",

keywords = "Bio-engineered Lacteal Complex (BLC), Methicillin-Resistant Staphylococcus Aureus (MRSA), Murine Peritonitis, Sepsis, Toxemia",

author = "Stoff, {Jesse A.} and Nix, {David E.} and DeYoung, {D. W.}",

note = "Funding Information: This investigation was supported, in part, by a research grant from Berlett, Inc.",

year = "2006",

month = oct,

doi = "10.1080/08923970601067045",

language = "English (US)",

volume = "28",

pages = "601--607",

journal = "Immunopharmacology and Immunotoxicology",

issn = "0892-3973",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model

AU - Stoff, Jesse A.

AU - Nix, David E.

AU - DeYoung, D. W.

N1 - Funding Information: This investigation was supported, in part, by a research grant from Berlett, Inc.

PY - 2006/10

Y1 - 2006/10

N2 - Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.

AB - Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.

KW - Bio-engineered Lacteal Complex (BLC)

KW - Methicillin-Resistant Staphylococcus Aureus (MRSA)

KW - Murine Peritonitis

KW - Sepsis

KW - Toxemia

UR - http://www.scopus.com/inward/record.url?scp=33845864713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845864713&partnerID=8YFLogxK

U2 - 10.1080/08923970601067045

DO - 10.1080/08923970601067045

M3 - Article

C2 - 17190737

AN - SCOPUS:33845864713

SN - 0892-3973

VL - 28

SP - 601

EP - 607

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

IS - 4

ER -

A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this